Perspectives on the Clinical Development of NRF2-Targeting Drugs

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor regulating cellular responses to oxidative stress and inflammation.
• Dysregulation of NRF2 is implicated in chronic diseases like neurodegenerative, cardiovascular, and metabolic disorders.
• NRF2 activation can inhibit carcinogenesis, but its role in established tumors necessitates targeted inhibition.

Purpose of the Study:

• To review electrophilic and non-electrophilic NRF2 activators for chronic diseases.
• To analyze the current status of NRF2 inhibitors in preclinical development.
• To explore the potential of in silico screening and medicinal chemistry for developing novel NRF2 modulators.

Main Methods:

• Literature review of NRF2 activators and inhibitors.
• Analysis of NRF2 regulation mechanisms, including Keap1-dependent degradation and GSK-3 phosphorylation.
• Discussion of clinical projections and proof-of-concept studies for NRF2 modulators.

Main Results:

• NRF2 activators show promise for treating chronic inflammatory and metabolic diseases.
• NRF2 inhibitors are in early stages of development but are essential for targeting tumors.
• Small molecules for targeted NRF2 modulation are anticipated through advanced computational and chemical approaches.

Conclusions:

• Targeted modulation of NRF2, either activation or inhibition, presents a significant therapeutic strategy for a range of diseases.
• Further research in medicinal chemistry and in silico screening is vital for advancing NRF2-targeted therapies.
• Understanding NRF2's dual role in disease prevention and tumor promotion is key to its clinical application.